Globus Medical, Inc. (GMED)

US — Healthcare Sector
Peers: BIO  PEN  HSIC  ALGN  DVA  GRFS  MOH  HQY  ATR 

Automate Your Wheel Strategy on GMED

With Tiblio's Option Bot, you can configure your own wheel strategy including GMED - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GMED
  • Rev/Share 20.593
  • Book/Share 32.7045
  • PB 2.662
  • Debt/Equity 0.0271
  • CurrentRatio 4.1299
  • ROIC 0.0735

 

  • MktCap 11651450659.0
  • FreeCF/Share 4.3093
  • PFCF 20.1024
  • PE 27.6317
  • Debt/Assets 0.0234
  • DivYield 0
  • ROE 0.0999

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade GMED BofA Securities Neutral Buy -- $91 Nov. 7, 2025
Upgrade GMED Truist Hold Buy -- $93 Nov. 7, 2025
Resumed GMED Stifel -- Hold -- $64 Oct. 28, 2025
Downgrade GMED BTIG Research Buy Neutral -- -- May 27, 2025
Upgrade GMED BofA Securities Underperform Neutral -- $97 Jan. 10, 2025

News

Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say
GMED
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say
Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates
GMED
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Globus Medical (GMED) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.60 per share a year ago.

Read More
image for news Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates
Globus Medical: Q4 Revenue Tops Forecast
GMED
Published: February 20, 2025 by: The Motley Fool
Sentiment: Positive

Medical technologies specialist Globus Medical (GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) of $0.84, exceeding the consensus forecast of $0.75, along with revenue that reached $657.3 million, topping expectations by $12.3 million.

Read More
image for news Globus Medical: Q4 Revenue Tops Forecast

About Globus Medical, Inc. (GMED)

  • IPO Date 2012-08-03
  • Website https://www.globusmedical.com
  • Industry Medical - Devices
  • CEO Keith W. Pfeil
  • Employees 5300

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.